Anavex Life Sciences Corp (AVXL)

[Steady_T]

While it is true that post hoc analyses is not what approvals are made of, it is also true that the regulators probably still see them if they are suggestive.
The primary trial data will drive the decision. Subgroup analyses can clarify how the efficacy is spread out across the trial population.

In the case of the AD trial the analysis is not post hoc. From the trial description on Clinicaltrials.gov.

Number of participants with pre-specified genetic variants
AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed